GLONGHUI, April 26 | Damo released a report indicating that after China Traditional Chinese Medicine, the leader in traditional Chinese medicine granules, announced last year's results, the bank reduced its profit estimates for the current year and next two years by about 5% to 6%, reflecting a reduction in sales forecasts for traditional Chinese medicine granules. The forecast was also extended to 2030, and the target price was raised from HK$4.8 to HK$5.4. The valuation was attractive, and the rating “increased”. According to the report, between 2020 and 2025, sales of traditional Chinese medicine granules are expected to grow at an average annual rate of 15% to 20%. With the opening up of the market, hospitals are committed to developing new financial resources outside of Western medicine. The Mainland Government has favorable policies on Chinese medicine granules, which are exempt from being included in pharmaceutical revenue control.